BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 15, BofA upgraded the company’s stock to “Buy” from “Neutral” with a price objective of $61, an increase from $52, given the company’s R&D pipeline, as reported by The Fly. As per the firm, 4-6 programs are expected to deliver key de-risking catalysts over the near term. It believes that the current weakness is a buying opportunity as conservative trough EPS offers a floor for the share price. ...